Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266695 · ClinicalTrials.gov registry record · Phase 3
Treatment for Completers of the Study B7A-MC-MBCM
A Phase 3 study, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
NCT00266695 is a Phase 3 study that has completed, run by Chromaderm. The registered enrollment target is 203 participants.
The verdict
NCT00266695, a Phase 3 study, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
Study Summary
To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.
Interventions
- DRUG Ruboxistaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266695
The ClinicalTrials.gov registry entry for NCT00266695 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chromaderm, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruboxistaurin is the first listed.
NCT00266695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266695 about?
NCT00266695 is a clinical study titled "Treatment for Completers of the Study B7A-MC-MBCM". To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning...
What is the current status of trial NCT00266695?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2006-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00266695?
The interventions under investigation include: Ruboxistaurin (DRUG).
Who is sponsoring clinical trial NCT00266695?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.